

NEUREN PHARMACEUTICALS LIMITED

ANNUAL GENERAL MEETING
Wednesday, 27 May, 2026

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	<i>For</i>	<i>Against</i>	<i>Discretionary (OpenVotes)</i>	<i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>	<i>Result</i>
1	RE-ELECTION OF DIRECTOR - JOE BASILE	NA	53,645,115 92.46%	4,305,931 7.42%	71,060 0.12%	2,641	56,578,836 92.59%	4,530,332 7.41%	121,806	Carried
2	AUDITOR REMUNERATION	NA	57,715,017 99.48%	228,630 0.39%	70,931 0.12%	10,169	60,209,097 98.54%	892,543 1.46%	129,334	Carried
3	ISSUE OF OPTIONS TO MANAGING DIRECTOR - JONATHAN PILCHER	NA	48,788,280 86.42%	7,599,324 13.46%	70,260 0.12%	66,883	51,702,461 86.66%	7,961,530 13.34%	66,983	Carried
4	AMENDMENTS TO THE COMPANY'S CONSTITUTION	NA	41,215,748 71.04%	16,725,242 28.83%	73,797 0.13%	9,960	43,662,959 71.52%	17,389,190 28.48%	178,825	Not Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item